It is very uncertain whether regimens containing clindamycin plus aminoglycoside changes microbiological clearance compared with regimens containing cephalosporin (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Different dosing regimens of aminoglycosides (daily showed no clear difference in increase in serum creatinine during treatment compared with 8 hourly) (low certainty).
Different dosing regimens of aminoglycosides (daily showed no clear difference in persistent bacteriuria after 1 to 3 days of treatment compared with 8 hourly) (low certainty).
Different dosing regimens of aminoglycosides (daily showed no clear difference in hearing impairment following treatment compared with 8 hourly) (low certainty).
Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in all serious adverse events compared with placebo/open control (high certainty).
Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in death from any cause compared with placebo/open control (high certainty).
Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in death or dependence (mRS 4–6) compared with placebo/open control (high certainty).
Summary of findings table ‐ Antifibrinolytic drug(s) leads to lower intracerebral haemorrhage expansion by 24 hours compared with placebo/open control (high certainty).
It is very uncertain whether summary of findings: split‐spinous process laminotomy changes incidence of postoperative instability compared with conventional laminectomy (very low certainty).
Summary of findings: split‐spinous process laminotomy showed no clear difference in incidence of perioperative complications compared with conventional laminectomy (low certainty).
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes clinical relapse (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) showed no clear difference in maintenance of clinical remission (24 to 52 weeks) compared with 5‐ASA (mesalazine) (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes withdrawal due to adverse events (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).